Tags

Type your tag names separated by a space and hit enter

Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Mult Scler Relat Disord. 2019 Sep; 34:100-102.MS

Abstract

Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.

Authors+Show Affiliations

Providence Neurological Specialties, Neurology-Multiple Sclerosis Attending, Providence St. Vincent Medical Center, Portland, OR, United States. Electronic address: meghan.romba@providence.org.Johns Hopkins University School of Medicine, Department of Neurology, Johns Hopkins Neurology Outpatient Services, Pathology Building, Room 509, 600 N. Wolfe Street, Baltimore, MD 21287, United States. Electronic address: snewsom2@jhmi.edu.Johns Hopkins University School of Medicine, Department of Neurology, Medicine, Epidemiology, and Pathology, Johns Hopkins Department of Neurology, Pathology Building, Room 509, 600 N. Wolfe Street, Baltimore, MD 21287, United States. Electronic address: jm@jhmi.edu.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

31252364

Citation

Romba, Meghan C., et al. "Acute Myocardial Infarction Associated With Initial Alemtuzumab Infusion Cycle in Relapsing-remitting Multiple Sclerosis." Multiple Sclerosis and Related Disorders, vol. 34, 2019, pp. 100-102.
Romba MC, Newsome SD, McArthur JC. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2019;34:100-102.
Romba, M. C., Newsome, S. D., & McArthur, J. C. (2019). Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 34, 100-102. https://doi.org/10.1016/j.msard.2019.06.022
Romba MC, Newsome SD, McArthur JC. Acute Myocardial Infarction Associated With Initial Alemtuzumab Infusion Cycle in Relapsing-remitting Multiple Sclerosis. Mult Scler Relat Disord. 2019;34:100-102. PubMed PMID: 31252364.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis. AU - Romba,Meghan C, AU - Newsome,Scott D, AU - McArthur,Justin C, Y1 - 2019/06/18/ PY - 2019/02/28/received PY - 2019/04/30/revised PY - 2019/06/17/accepted PY - 2019/6/30/pubmed PY - 2020/2/23/medline PY - 2019/6/29/entrez KW - Acute coronary syndrome KW - Adverse events KW - Alemtuzumab KW - Multiple sclerosis SP - 100 EP - 102 JF - Multiple sclerosis and related disorders JO - Mult Scler Relat Disord VL - 34 N2 - Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors. SN - 2211-0356 UR - https://www.unboundmedicine.com/medline/citation/31252364/Acute_myocardial_infarction_associated_with_initial_alemtuzumab_infusion_cycle_in_relapsing_remitting_multiple_sclerosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(19)30268-8 DB - PRIME DP - Unbound Medicine ER -